



AF 1614 #

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No.: 09/717,746  
Filing Date: 11/21/2000  
Applicants: Herbert M. Dean et al.  
Title: CARDIOPROTECTIVE DOSAGE UNITS  
Art Unit: 1614  
Examiner: Donna A. Jagoe

RECEIVED  
NOV 29 2002  
TECH CENTER 1600/2900

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Enclosed for filing in the above-referenced patent application please find an Amendment and Request for Reconsideration Pursuant to 37 CFR §1.116, a Petition for Extension of Time, a check in the amount of \$55.00 for the extension, and a return postcard.

Respectfully submitted,

Dated: 11/20/02

Robert R. Deleault, Esq.  
Reg. No. 39,165  
Attorney for Applicants  
41 Brook Street  
Manchester, NH 03104  
Tel. (603) 668-1971

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on:

November 20, 2002  
Robert R. Deleault  
Robert R. Deleault



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

NOV 29 2002

RECEIVED

#8/B  
(NE)  
JRP  
12/4/02

U.S. Serial No.: 09/717,746  
Filing Date: 11/21/2000  
Applicants: Herbert M. Dean et al.  
Title: CARDIOPROTECTIVE DOSAGE UNITS  
Art Unit: 1614  
Examiner: Donna A. Jagoe

Paper No. \_\_\_\_\_

**AMENDMENT AND REQUEST FOR RECONSIDERATION**  
**PURSUANT TO 37 CFR § 1.116**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Applicants respectfully request that the following amendments to the Application be entered:

**IN THE CLAIMS:**

Please substitute the following claims for the like numbered claims in the application:

1. A medicament dosage unit consisting essentially of a beta-adrenergic blocker and a platelet inhibitor together in a single dosage unit quantity sufficient to provide a cardiovascular protective dosage.
9. A method of treating cardiovascular disease said method comprising:  
formulating a single dosage unit consisting essentially of a beta-adrenergic blocking agent and a platelet inhibitor in a single dosage unit quantity sufficient to provide a cardiovascular protective dosage; and  
administering said single dosage unit to a patient.

OK to  
enter  
12/13/02  
JRP